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Background: Glucose fluctuation has been recognized as a residual risk apart from dyslipidemia for the development
of coronary artery disease (CAD). This study aimed to investigate the association between glucose fluctuation and
coronary plaque morphology in CAD patients.
Methods: This prospective study enrolled 72 consecutive CAD patients receiving adequate lipid-lowering therapy.
They were divided into 3 tertiles according to the mean amplitude of glycemic excursions (MAGE), which represents
glucose fluctuation, measured by continuous glucose monitoring (tertile 1; <49.1, tertile 2; 49.1 ~ 85.3, tertile 3; >85.3).
Morphological feature of plaques were evaluated by optical coherence tomography. Lipid index (LI) (mean lipid
arc × length), fibrous cap thickness (FCT), and the prevalence of thin-cap fibroatheroma (TCFA) were assessed in
both culprit and non-culprit lesions.
Results: In total, 166 lesions were evaluated. LI was stepwisely increased according to the tertile of MAGE (1958 ± 974
[tertile 1] vs. 2653 ± 1400 [tertile 2] vs. 4362 ± 1858 [tertile 3], p <0.001), whereas FCT was the thinnest in the tertile 3
(157.3 ± 73.0 μm vs. 104.0 ± 64.1 μm vs. 83.1 ± 34.7 μm, p <0.001, respectively). The tertile 3 had the highest prevalence
of TCFA. Multiple linear regression analysis showed that MAGE had the strongest effect on LI and FCT (standardized
coefficient β = 0.527 and −0.392, respectively, both P <0.001). Multiple logistic analysis identified MAGE as the only
independent predictor of the presence of TCFA (odds ratio 1.034; P <0.001).
Conclusions: Glucose fluctuation and hypoglycemia may impact the formation of lipid-rich plaques and thinning
of fibrous cap in CAD patients with lipid-lowering therapy.
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Dyslipidemia, especially a high low-density lipoprotein
(LDL) cholesterol level, has been recognized as the most
important promoter of atherosclerotic cardiovascular
disease. A large number of clinical trials have reported
beneficial effects of statins for primary and secondary pre-
vention and improved all-cause mortality in association
with lowering LDL cholesterol levels [1, 2]. However, the
insufficiency of risk reduction with lipid-lowering therapy
alone has accumulated attention on the unmet need for
residual clinical risk management.
Diabetes mellitus (DM) is also a major risk factor for
coronary artery disease (CAD) [3]. Several trials have dem-
onstrated that hyperglycemia is relevant to the progression
of atherosclerosis [4]. Recent investigations have revealed
that compared with continuous hyperglycemia, large glu-
cose fluctuation, such as postprandial hyperglycemia,
might be one of the most deleterious factors in cardiovas-
cular disease [5, 6]. Growing evidence further indicates
that hypoglycemia has a negative impact on cardiovascular
condition [7, 8]. With the recent emergence of continuous
glucose monitoring (CGM) system, it has become possible
to evaluate daily glucose fluctuation, including time in
hyper- and hypoglycemia, in clinical practice. However,
whether glucose fluctuation, including hypoglycemia, mayFig. 1 Study population. Seventy-two were enrolled in this study. CGM: co
low-density lipoprotein-cholesterol; LVEF: left ventricular ejection fraction; OCThave an impact on coronary plaque properties remains
unclear.
Optical coherence tomography (OCT) is a high-
resolution intravascular imaging modality that enables
detailed assessment of coronary plaque character, such
as lipid-rich, calcified, and fibrous, as well as fibrous cap
thickness and vulnerable features . The aim of the
present study was to investigate the relationship between
glucose fluctuation and coronary plaque properties ana-
lyzed by CGM and OCT, respectively.
Methods
Patient population
Seventy-two consecutive patients who had been referred
for percutaneous coronary intervention (PCI) for coron-
ary artery disease (CAD) during the period from June
2012 to April 2015 and who fulfilled the following inclu-
sion criteria were enrolled in this prospective registry
(Fig. 1): 20–80 years of age under adequate treatment of
dyslipidemia; LDL cholesterol levels <120 mg/dL under
statin administration or <100 mg/dL under other treat-
ment for dyslipidemia including lifestyle management.
The study exclusion criteria were 1) PCI for acute cor-
onary syndrome; 2) unsuitable anatomy for OCT; 3) pre-
sented with cardiogenic shock or left ventricular ejectionntinuous glucose monitoring; DM: diabetes mellitus; LDL-cholesterol:
: optical coherence tomography; PCI: percutaneous coronary intervention
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(such as active infection, inflammatory arthritis, or con-
nective tissue disease) or malignancy; and 5) renal insuf-
ficiency with baseline creatinine level ≥2.0 mg/dL,
including dependence on hemodialysis. We divided the
patients into three groups according to the tertile of
mean amplitude of glycemic excursions (MAGE, tertile
1; <49.1, tertile 2; 49.1 ~ 85.3, tertile 3; >85.3). MAGE,
which was first proposed by Service et al., [9] represents
fluctuations in blood glucose levels over a 24-h period
and was calculated from the daily variations in blood
glucose level, measured continuously by CGM over a
period of 2 days.
This study was approved by the ethics committee of
Kobe University and was carried out according to the
guidelines of the Declaration of Helsinki. All enrolled
study patients provided their written informed consent
for enrolment into the study.
Study protocol
On admission, a blood sample analysis was performed
under fasting conditions to evaluate levels of creatinine,
glycated hemoglobin (HbA1c), total cholesterol, LDL
cholesterol, high-density lipoprotein cholesterol, triglyc-
erides, and C-reactive protein. In addition, all patients
underwent a 75-g oral glucose tolerance test (OGTT),
and levels of plasma glucose and immunoreactive insulin
were evaluated just before and 120 min after the oral
glucose load. Subcutaneous interstitial glucose levels
were monitored over a period of 3 consecutive days using
the iPro™2 CGM system (Medtronic, Northridge, CA)
(Fig. 2). After the CGM examination, three vessels were
subjected to OCT examination, including both culprit le-
sions for PCI and non-culprit lesions. Culprit lesions were
identified by analyzing pre-crisis and inter-crisis electro-
cardiograms, left ventricular wall motion abnormalities,
and angiographic lesion appearance. Non-culprit lesions
were defined as angiographically intermediate lesions
(diameter of stenosis 30–70 %) with an identified plaque
narrowing lumen area <4 mm2 by OCT.
Continuous glucose monitoring system
CGM was performed for 3 consecutive days before PCI,
and the daily glucose profile was analyzed using dataFig. 2 Study protocol. On admission, a blood sample analysis and 75-g oral g
Subcutaneous interstitial glucose levels were monitored over a period of 3 co
CGM examination, 3 vessels were subjected to optical coherence tomographyobtained on days 2 and 3 to avoid any bias due to inser-
tion or removal of the sensor. In all patients, CGM ana-
lysis software (CareLink iPro, Medtronic, Northridge,
CA) calculated the median of the variables measured
on days 2 and 3: 24-h mean glucose levels, time in
hyperglycemia/hypoglycemia, and MAGE. Time in
hyperglycemia and hypoglycemia was defined as the
time when blood glucose levels were above 140 mg/dL
and under 70 mg/dL, respectively. All patients received
optimal meals (25–28 kcal/kg of ideal body weight;
60 % carbohydrate, 15–20 % protein, and 20–25 % fat)
during CGM.
OCT imaging
Images were acquired using a commercially available,
frequency-domain OCT imaging system (ILUMIEN; St.
Jude Medical Inc., St Paul, MN, USA). In this system, a
2.7-Fr OCT imaging catheter is advanced distal to the
lesion, and automated pullback is initiated in concord-
ance with blood clearance by the injection of contrast
media. All images were de-identified and digitally stored.
OCT analysis
All OCT images were analyzed by 2 independent investi-
gators (MK, HO), who were blinded to the angiographic
and clinical findings, using Off-line Review Workstation.
When discordance in terms of qualitative plaque morph-
ology occurred between observers, a consensus reading
was obtained with third investigator (TS). Using OCT
examination, a lipid-rich plaque was defined as a dif-
fusely bordered, signal-poor region (lipid pools) with
overlying signal-rich bands, corresponding to fibrous
caps (Fig. 3a) [10]. The lipid arc was measured at every
1-mm interval throughout the length of each lesion, and
the values were averaged. Lipid length was also mea-
sured on longitudinal view. Lipid index (LI) was defined
as the mean lipid arc multiplied by lipid length [11].
Fibrous cap was defined as a signal-rich homogenous
layer overlying the lipid-rich plaque [12]. The thinnest
part of the fibrous cap was measured 3 times, and its
average was defined as fibrous cap thickness (FCT) [13].
Calcification was also recorded when an area consisted
of a signal-poor or heterogeneous region with a sharply
delineated border (Fig. 3b) [14]. Calcification arc waslucose tolerance test (OGTT) were performed under fasting conditions.
nsecutive days using continuous glucose monitoring (CGM). After the
(OCT) examination
Fig. 3 Representative optical coherence tomography images. a The
representative case of lipid-rich plaque and the measurement of fibrous
cap thickness. Lipid-rich plaque was defined as a diffusely bordered,
signal-poor region (lipid pools) with overlying signal-rich bands,
corresponding to fibrous caps. The fibrous cap thickness overlying
a lipid-rich plaque was 140 μm at its thinnest part (arrow). b The
representative case of calcification. Calcification was also recorded
when an area consisted of a signal-poor or heterogeneous region
with a sharply delineated border. c The representative case of thin-cap
fibroatheroma (TCFA) The fibrous cap thickness of this lesion was
50 μm (white arrows), and this plaque was diagnosed as TCFA
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of each lesion, and the values were averaged. Calcifica-
tion length was also measured on longitudinal view. As
with LI, calcification index (CI) was defined as the mean
calcification arc multiplied by calcification length. Intra-
class correlation coefficients for intra- and interobserverreliabilities were 0.982 and 0.958, respectively, for the
lipid arc, and 0.992 and 0.963, respectively, for the calci-
fication arc.
The presence of TCFA, macrophage infiltration, micro-
channels, and thrombus was also assessed. Thin-cap
fibroatheroma (TCFA) was defined as a thin fibrous cap
(<65 μm) overlying a lipid-rich plaque (>90°) (Fig. 3c) [15].
Microchannels were defined as signal-poor voids that
were sharply delineated in multiple contiguous frames [14,
16]. Intracoronary thrombus was defined as a mass (diam-
eter ≥ 250 μm) attached to the luminal surface or floating
within the lumen, including red (red blood cell-rich)
thrombus, which showed high backscattering with high
attenuation (resembling blood), and white (platelet-rich)
thrombus, which showed less backscattering, was homo-
geneous, and had low attenuation [14, 17]. Intraobser-
ver and interobserver agreements for the detection of
TCFA were within the acceptable range (intraobserver,
kappa = 0.899; interobserver, kappa = 0.863).
Statistical analysis
All data are presented as mean ± SD or proportions. Dif-
ferences in continuous parameters among the 3 groups
were calculated using a one-way analysis of variance for
parametric data. The Tukey test was used as a post hoc
analysis for continuous variables. Non-parametric pa-
rameters were compared using the Games–Howell test.
Categorical variables were presented using frequency
counts, and intergroup comparisons were analyzed by
Fisher's exact test. Simple linear correlations were calcu-
lated using the concept of least squares and by deter-
mining the Pearson correlation coefficient, r. Multiple
regression models were used to explore the influence of
different variables on LI and FCT and to adjust for co-
variates. Multivariate logistic regression was performed
to assess the impact of a set of factors on TCFA. Univar-
iate analysis was performed first, and all variables that
satisfied P < 0.2 were entered en bloc into the multivari-
ate model, along with age, sex and medications as
background variables. Intra-observer and interobserver
reliabilities were estimated by the intraclass correlation
coefficient for continuous measurement. To assess
intraobserver and interobserver variabilities, categorical
data were compared with the kappa test of concord-
ance, and a Bland-Altman plot was used for continuous
data. The sample size was estimated based on the pre-
vious report from Torimoto K, et al. [18]. They showed
that glucose fluctuations in blood play a significant role
in vascular endothelial dysfunction in 57 patients with
type 2 diabetes in a sample size of 57 subjects provided
power of 85 % at a significance level of 0.05 (r = 0.4)
[18]. Referring to this report, we calculated the appro-
priate sample size. The association between glucose
variability and plaque morphology in a sample size of
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level of 0.05 (r =0.50). Analyses were performed using
commercially available software (IBM SPSS version 21,
IBM Corp., Somers, New York).
Results
Baseline patient characteristics
Between June 2012 and April 2015, a total of 72 patients
were enrolled. 85 % of the subjects presented with glu-
cose intolerance, including newly and formerly diag-
nosed DM and impaired glucose tolerance. Baseline
patient characteristics, medications on admission and
variables measured by CGM are shown in Table 1. No
significant differences among three group were observed
in the baseline characteristics, except for the prevalence
of DM and glycemic variables such as HbA1c, 1,5-AG,
and glycoalbumin levels. According to the 75-g OGTT
data, 2-h PG levels was significantly the highest in the
tertile 3 among the three group. Medications on admis-
sion did not differ among the three groups, except for
diabetes drugs usage. All variables obtained by CGM
had significantly greater values in the tertile 3 than the
other groups except for minimum blood glucose.
Plaque characteristics obtained by OCT examination
A total of 166 plaques including 64 culprit lesions and 102
non-culprit lesions were identified in 72 patients. The
plaque characteristics are shown in Table 2. Tertile 3 had
the highest prevalence of lipid-rich plaque, TCFA, and
microchannel, whereas there was no difference in the fre-
quency of calcification among three groups. Tertile 3 also
had a significantly wider lipid arc, a longer lipid length,
and a higher LI than other two groups, while CI did not
differ among three groups (Fig. 4a and c). Also, FCT was
significantly thinner in tertile 3 (Fig. 4b).
Association between OCT measurements and markers of
diabetic control and nonglycemic metabolic variables
Lipid and calcification variables were tested for simple
linear correlations against markers of glucose control
and other laboratory variables (Table 3). MAGE had the
strongest correlation with LI (r = 0.541; P < 0.001). Mean
blood glucose, the time in hyperglycemia, HbA1c, and
duration of DM were also observed to significantly cor-
relate with LI. FCT was negatively correlated with
MAGE and the time in hyper- and hypoglycemia, al-
though there was no correlation between FCT and DM
duration. LI and FCT did not correlate with other clin-
ical or laboratory variables. Calcification length and CI
did not correlate with any diabetic or nonglycemic vari-
ables, except a significant positive correlation between
CI and DM duration.
Multiple linear regression analysis was performed to
assess the independent effects of diabetic parameters onLI and FCT (Table 4). Multivariate analysis demonstrated
that a larger MAGE was independently associated with a
higher LI and thinner FCT (standardized coefficient
β = 0.527 and −0.392, respectively; both P < 0.001). Also, in
multivariate analysis, longer duration of hypoglycemia sig-
nificantly correlated with thinner FCT.
Association between TCFA and clinical and laboratory
variables
Multivariate analysis was performed to identify inde-
pendent risk factors for TCFA (Table 5). Univariate
analysis was first conducted to identify potential factors,
such as medications, glucose control and other labora-
tory variables, for TCFA. All variables with P < 0.2 on
univariate analysis were tested by multivariate analysis.
In all plaques, MAGE was the only independent pre-
dictor of TCFA (odds ratio 1.034, 95 % confidence inter-
val 1.019–1.049, P < 0.001).
DM vs. non-DM patients
We divided the patients into two groups according to
whether or not they met the DM criteria (DM group and
non-DM group) and the correlation with MAGE and
OCT findings assessed in two groups. We detected 83 pla-
ques in 36 DM patients (2.3 plaques/patient) and 83 pla-
ques in 36 non-DM patients (2.3 plaques/patient). In both
the DM group and the non-DM group, MAGE signifi-
cantly correlated with LI and FCT (DM group; r = 0.459
and −0.384, both P < 0.001, non-DM group; r = 0.514 and
−0.474; both P < 0.001, respectively) (Fig. 5). In both groups,
multivariate analysis demonstrated that larger MAGE was
significantly associated with higher LI and thinner FCT
(Table 4).
Discussion
The current study represents an in vivo report to assess
the impact of glucose fluctuations on coronary plaque
properties using CGM and OCT in patients with CAD
and under statin administration or other dyslipidemia
management. The novel findings of this study can be sum-
marized as follows: 1) in CAD patients under adequate
treatment for dyslipidemia, glucose fluctuation might be
an important contributing factor to the formation of lipid-
rich plaque; 2) a longer time in hypoglycemia was signifi-
cantly correlated with a thinner FCT; and 3) coronary
plaque calcification was associated with the duration of
DM rather than daily glucose fluctuation.
Association between glucose fluctuation and development
of coronary artery disease
The present study showed that glucose fluctuation had a
stronger correlation with LI and FCT than any other
variables, based on OCT examination. Several in vitro in-
vestigations have reported that glucose variability might
Table 1 Baseline patient characteristics
Overall
(n = 72)
Tertile 1 (MAGE <49.1)
(n = 24)





Age (years) 69.9 ± 11.3 69.2 ± 12.0 71.1 ± 9.8 69.5 ± 12.3 0.82
BMI (kg/m2) 24.1 ± 3.0 23.7 ± 2.6 24.5 ± 2.4 24.0 ± 3.9 0.64
Male 58 (80.6) 19 (79.2) 19 (79.2) 20 (83.3) 0.91
DM 36 (50.0) 6 (25.0) 11 (45.8) 19 (79.2) 0.001
Hypertension 53 (73.6) 19 (79.2) 16 (66.7) 18 (75.0) 0.61
Dyslipidemia 60 (83.3) 18 (75.0) 22 (91.7) 20 (83.3) 0.30
Smoking 49 (68.1) 15 (62.5) 16 (66.7) 18 (75.0) 0.52
Current 19 (26.4) 6 (25.0) 12 (50.0) 9 (37.5)
Former (quit >3 months) 30 (41.7) 9 (37.5) 4 (16.7) 9 (37.5)
Prior myocardial infarction 14 (19.4) 4 (16.7) 5 (20.8) 5 (20.8) 0.92
Prior PCI 33 (45.8) 11 (45.8) 12 (50.0) 14 (58.3) 0.85
Systolic blood pressure (mmHg) 121.5 ± 11.4 124.1 ± 11.2 121.4 ± 10.5 119.1 ± 12.4 0.32
Diastolic blood pressure (mmHg) 64.7 ± 9.0 64.2 ± 8.7 66.3 ± 9.3 63.5 ± 9.1 0.55
Left ventricular ejection fraction (%) 59.8 ± 9.6 57.5 ± 12.8 60.8 ± 8.7 61.1 ± 5.9 0.37
Duration of DM (years) 3.7 ± 7.7 0 3.5 ± 6.7 7.4 ± 10.5 0.003
HbA1c (NGSP) (%) 6.3 ± 1.0 5.8 ± 0.4 6.1 ± 0.6 6.9 ± 1.2 <0.001
1,5-AG (μg/mL) 15.8 ± 8.4 20.6 ± 10.2 15.5 ± 6.0 10.8 ± 5.3 <0.001
Glycoalbumin (%) 16.2 ± 3.5 14.6 ± 1.7 15.1 ± 2.7 19.2 ± 3.7 <0.001
75-g OGTT
Fasting PG (mg/dL) 101 ± 23 89 ± 10 106 ± 29 107 ± 22 0.009
2-h PG (mg/dL) 206 ± 78 159 ± 45 209 ± 65 255 ± 90 <0.001
Fasting IRI (μU/mL) 6.9 ± 5.9 6.9 ± 5.3 9.0 ± 7.7 4.6 ± 3.0 0.044
2-h IRI (μU/mL) 83.6 ± 65.7 94.9 ± 59.9 92.0 ± 71.1 59.8 ± 62.6 0.156
HOMA R 1.8 ± 2.3 1.5 ± 1.1 2.7 ± 3.5 1.2 ± 0.7 0.056
HOMA β 82.5 ± 72.6 109.5 ± 95.0 83.3 ± 48.8 50.9 ± 53.8 0.024
Total cholesterol (mg/dL) 155.3 ± 27.9 161.8 ± 30.3 149.0 ± 21.3 154.9 ± 30.8 0.29
LDL cholesterol (mg/dL) 88.7 ± 19.1 88.5 ± 17.5 87.2 ± 17.4 90.4 ± 22.6 0.84
HDL cholesterol (mg/dL) 45.9 ± 11.3 46.1 ± 11.8 44.2 ± 11.0 47.5 ± 11.4 0.61
Triglyceride (mg/dL) 124.8 ± 57.9 125.8 ± 68.8 128.7 ± 51.4 119.8 ± 54.5 0.87
CRP (mg/dL) 0.21 ± 0.33 0.14 ± 0.23 0.18 ± 0.24 0.30 ± 0.47 0.25
Creatinine (mg/dL) 0.93 ± 0.28 0.91 ± 0.21 0.88 ± 0.20 1.00 ± 0.38 0.30
Medication on admission
Aspirin 57 (79.2) 19 (79.2) 20 (83.3) 18 (75.0) 0.78
Thienopyridine 32 (44.4) 10 (41.7) 10 (41.7) 12 (50.0) 0.80
Statin 54 (75.0) 17 (70.8) 20 (83.3) 17 (70.8) 0.51
EPA 3 (4.2) 2 (8.3) 1 (4.2) 0 (0.0) 0.35
Ezetimibe 5 (6.9) 0 (0.0) 5 (20.8) 0 (0.0) 0.005
Fibrate 2 (2.8) 0 (0.0) 0 (0.0) 2 (8.3) 0.13
ACE-I/ARB 40 (55.6) 12 (50.0) 13 (54.2) 15 (62.5) 0.75
Beta-blocker 26 (36.1) 7 (29.2) 9 (37.5) 10 (41.7) 0.64
Insulin 3 (4.2) 0 (0.0) 0 (0.0) 3 (12.5) 0.044
Metformin 6 (8.3) 0 (0.0) 1 (4.2) 5 (20.8) 0.022
SU 9 (12.5) 0 (0.0) 2 (8.3) 7 (29.2) 0.007
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Table 1 Baseline patient characteristics (Continued)
α-GI 5 (6.9) 0 (0.0) 2 (8.3) 3 (12.5) 0.22
DPP4-I 12 (16.7) 0 (0.0) 5 (20.8) 7 (29.2) 0.020
Variables measured by the continuous glucose monitoring system
MAGE (mg/dL) 70 ± 31 38 ± 8 66 ± 10 106 ± 19 <0.001
Mean BG (mg/dL) 132 ± 29 116 ± 9 127 ± 25 153 ± 35 <0.001
Max BG (mg/dL) 212 ± 55 165 ± 22 210 ± 48 262 ± 41 <0.001
Min BG (mg/dL) 77 ± 28 78 ± 14 72 ± 28 79 ± 36 0.70
Time in hyperglycemia (hours) 19.0 ± 15.4 7.6 ± 6.3 18.30 ± 14.8 31.6 ± 13.3 <0.001
Time in hypoglycemia (hours) 1.4 ± 2.7 0.3 ± 0.6 1.4 ± 1.9 2.4 ± 4.0 0.023
Values are mean ± SD or no. (%) 1,5 AG: 1,5 anhydroglucitol; 75 g OGTT: 75-g oral glucose tolerance test; α-GI: α-glucosidase inhibitor; ACE-I: angiotensin converting
enzyme-inhibitor; ARB: angiotensin II receptor blocker; BG: blood glucose; BMI: body mass index; CABG: coronary artery bypass graft; CRP: C-reactive protein; DM:
diabetes mellitus; DPP4-I: dipeptidyl peptidase-4 inhibitor; EPA: eicosapentaenoic acid; HbA1c: glycated hemoglobin; HDL cholesterol: high-density lipoprotein
cholesterol; HOMA B: homeostasis model assessment beta; HOMA R: homeostasis model assessment ratio; IRI: immunoreactive insulin; LDL cholesterol: low-density
lipoprotein cholesterol; MAGE: mean amplitude of glycemic excursion; PCI: percutaneous coronary intervention; PG: plasma glucose , Time in hyperglycemia and
hypoglycemia were defined as the time when blood glucose levels were above 140 mg/dL and under 70 mg/dL, respectively
Table 2 Plaque characteristics
Overall
(n =166)
Tertile 1 (MAGE <49.1)
(n =55)





Culprit lesion 64 (38.6) 20 (36.4) 21 (42.0) 23 (37.7) 0.83
Lipid-rich
plaque
91 (54.8) 22 (40.0) 31 (62.0) 38 (62.3) 0.026
Lipid length
(mm)
16.1 ± 6.7 13.2 ± 5.0 15.0 ± 6.2 19.5 ± 7.1 <0.001
Mean lipid arc 183.1 ± 51.9 147.1 ± 37.2 173.5 ± 43.7 223.4 ± 41.0 <0.001
Calcification 84 (50.6) 25 (45.4) 29 (58.0) 30 (49.2) 0.42
Calcification
length (mm)
5.3 ± 3.8 5.6 ± 3.7 4.3 ± 2.7 6.1 ± 4.6 0.21
Mean
calcification arc
119.6 ± 71.3 125.8 ± 73.0 90.5 ± 42.6 141.7 ± 83.2 0.019
TCFA 37 (22.3) 4 (7.3) 9 (18.0) 24 (39.3) <0.001
Microchannel 99 (59.6) 23 (41.8) 29 (58.0) 47 (77.0) 0.001
Thrombus 13 (7.8) 1 (1.8) 5 (10.0) 7 (11.5) 0.12
Plaque location 0.79
RCA
Proximal 28 (16.9) 8 (14.5) 9 (18.0) 11 (18.0)
Mid 12 (7.2) 5 (9.1) 3 (6.0) 4 (6.6)
Distal 8 (4.8) 1 (1.8) 5 (10.0) 2 (3.3)
LAD
Proximal 34 (20.5) 11 (20.0) 9 (18.0) 14 (22.9)
Mid 27 (16.2) 8 (14.5) 10 (20.0) 9 (14.7)
Distal 10 (6.0) 4 (7.3) 4 (8.0) 2 (3.3)
LCx
Proximal 13 (7.8) 7 (12.7) 1 (2.0) 5 (8.2)
Mid 26 (15.7) 8 (14.5) 7 (14.0) 11 (18.0)
Distal 8 (4.8) 3 (5.5) 2 (4.0) 3 (4.9)
Values are mean ± SD or no. (%) LAD: left anterior descending artery; LCx: left circumflex artery; RCA: right coronary artery; TCFA: thin-cap fibroatheroma
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Fig. 4 Comparison of OCT quantitative findings in plaque properties among 3 groups. a Lipid index (LI). b Fibrous cap thickness (FCT). c
Calcification index (CI) LI was stepwisely increased according to the tertile of MAGE (1958 ± 974 [tertile 1] vs. 2653 ± 1400 [tertile 2] vs. 4362
± 1858 [tertile 3], p <0.001, respectively) (a), whereas FCT was the thinnest in the tertile 3 (157.3 ± 73.0 μm vs. 104.0 ± 64.1 μm vs. 83.1 ± 34.7
μm, p <0.001, respectively) (b). CI did not differ among the three group (417 ± 968 vs. 242 ± 370 vs. 493 ± 842, p = 0.288, respectively) (c)
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vascular injury, compared with exposure to constant high
glucose [18, 19]. Schisano et al. reported that in vitro, pro-
longed exposure to oscillating glucose generated a more
detrimental condition in terms of oxidative stress and
DNA damage for endothelial cells than constant high
glucose, caused by hyperactivation of p53. Other in vivo
investigations also suggested that glucose fluctuation may
be involved in the development of vascular injury, com-
pared with constant high blood glucose [5, 20, 21]. Mita
et al. demonstrated that oscillations in blood glucose
concentrations accelerated macrophage adhesion to the
endothelial surface and the formation of arteriosclerotic
lesions independent of lipid profile in apolipoprotein
E-deficient mice [20]. Teraguchi I, et al. reported that
glycemic fluctuation assessed by MAGE is significantly
associated with coronary plaque rupture in patients with








Lipid length 0.369** 0.292** 0.349** 0.071
Lipid mean arc 0.615** 0.324** 0.397** 0.232**
Lipid index 0.541** 0.340** 0.405** 0.149
Fibrous cap
thickness
−0.430** −0.105 −0.192** −0.316**
Calcification
length
0.099 0.065 0.149 0.132
Calcification
mean arc
0.154 0.236* 0.253* 0.040
Calcification
index
0.101 0.099 0.166* 0.085
*P < 0.05; **P < 0.001. BG: blood glucose; CRP, C-reactive protein; DM: diabetes mell
cholesterol; LDL cholesterol: low-density lipoprotein cholesterol; MAGE: mean amplistudy also reported that compared with a marker of aver-
aged blood glucose level such as HbA1c, MAGE was a
more contributing factor of plaque vulnerability. These
investigations suggest that daily glucose fluctuation could
have a more ominous impact on the function of endothe-
lial cells to promote atherosclerosis, leading to the ad-
vancement of plaque vulnerability. Meanwhile, the present
study found no relationship between glucose fluctuation
and coronary calcification. Although DM patients have
been recognized to have a higher incidence of coronary
calcification than non-DM patients, few investigations
have reported that glucose fluctuation also could be
associated with coronary calcification. Therefore, future
studies are needed to further elucidate this point.
Several previous studies reported that oxidative stress is
not related to glucose fluctuation in type 1 diabetes [22, 23].
On the other hand, some studies investigated that glu-








0.173* 0.193* −0.065 −0.044 0.019 −0.061
0.330** 0.268** 0.173 −0.017 −0.018 0.286**
0.268* 0.257** 0.043 −0.053 0.037 0.068
−0.097 −0.046 −0.039 0.113 0.041 −0.149
−0.105 0.102 0.171 0.094 −0.053 0.026
−0.022 0.184 0.159 0.081 −0.029 −0.171
−0.047 0.227** −0.005 0.143 −0.034 −0.108
itus; HbA1c: glycated hemoglobin; HDL cholesterol: high-density lipoprotein
tude of glycemic excursion
Table 4 Linear multivariate analyses using (A) lipid index and
(B) fibrous cap thickness as the dependent variable, (1) In all
patients (n = 166), (2) in DM patients (n = 83), and (3) in non-DM
patient (n = 83)









MAGE 31.9 4.239 0.527 7.541 <0.001
Mean BG 10.4 5.075 0.143 2.051 0.042
(B)
MAGE −0.868 0.171 −0.392 −5.076 <0.001
Time in
hypoglycemia
−3.789 1.828 −0.160 −0.160 0.040
(2) in DM groups
(A)
MAGE 35.0 6.554 0.515 5.346 <0.001
(B)
MAGE −0.906 0.212 −0.433 −4.265 <0.001
(3) in non-DM patients
(A)
MAGE 31.9 5.633 0.532 5.661 <0.001
(B)
MAGE −1.357 0.280 −0.474 −4.847 <0.001
BG: blood glucose; MAGE: mean amplitude of glycemic excursion
Kuroda et al. Cardiovascular Diabetology  (2015) 14:78 Page 9 of 11on oxidative stress than chronic sustained hyperglycemia
in type 2 diabetes [5]. In the present study, patients with
type 1 diabetes were not included. An explanation for the
lack of correlation between glucose fluctuation and oxida-
tive stress may be that, unlike those with type 2 diabetes,
those with type 1 diabetes are not sensitive to glucose
variability as a stimulator of oxidative stress, because of
different underlying pathophysiological conditions, such as
dyslipidemia, smoking, obesity and other risk factors [23].
The impact of hypoglycemia on coronary plaque
vulnerability
In the present study, the longer time in hypoglycemia
was associated with a thinner FCT, suggesting thatTable 5 Univariate and multivariate logistic regression analyses for d
Variables Univariate




Time in hypoglycemia 1.105 0.983-1.242
1,5 AG: 1,5 anhydroglucitol; CI: confidence interval; HbA1c: glycated hemoglobin; Mhypoglycemia may have an association with plaque
vulnerability. The ACCORD trial revealed that severe
hypoglycemia was strongly associated with increased
risks of adverse clinical outcomes [7]. To date,
hypoglycemia has been recognized to induce the activa-
tion of the sympathetic nervous system [8], followed by
elevated blood pressure and vasoconstriction [24].
Gimenez et al. suggested that repeated hypoglycemic
episodes are associated with a worsening of subclinical
atherosclerosis profile represented not only by abnor-
malities in endothelial function but also by an increase
in intima-media thickness [25]. Furthermore, a recent
in vitro study reported that repetitive hypoglycemia en-
hanced monocyte adhesion to endothelial cells through
enhanced adrenaline activity [26]. These observations
suggest hypoglycemia might have some effects on the
progression of vulnerable plaques. Moreover, although
these data lead to the hypothesis that inhibition of glucose
fluctuation is potentially an important intervention in the
prevention of cardiovascular disease, a large-scale pro-
spective study is warranted to evaluate whether additional
glucose fluctuation control, including hypoglycemia, will
decrease the progression of plaque vulnerability and late
clinical events.
Limitations
This study has several limitations. First, as a single-center
study with a relatively small number of patients, a poten-
tial risk of patient selection bias exists. Second, we only
assessed patients with stable angina pectoris. We excluded
ACS patients from this study because those population
was highly heterogeneous with multiple confounding
factors, such as uncontrolled dyslipidemia, stress hypergly-
cemia, drastic changes in diet and medications after
admission. Further study is warranted including ACS pa-
tients since those might be a better target to address the
influence of MAGE on plaque characteristics because vul-
nerable plaques are more frequently found. Third, we did
not validate the OCT findings with histological findings;
therefore, the regions identified as TCFA were not con-
firmed to contain a large necrotic core overlapping with a
thin cap. Fouth, we excluded patients whose LDL choles-
terol level was >120 mg/dL under statin treatment or
>100 mg/dL without statins and included only patientseterminants of TCFA
Multivariate
P value OR 95 % CI P value




AGE: mean amplitude of glycemic excursion; OR: odds ratio
Fig. 5 The correlation between mean amplitude of glycemic excursion (MAGE) and lipid index (LI) and fibrous cap thickness (FCT). This figure shows
the correlation between MAGE and LI and FCT in a DM and b non-DM groups
Kuroda et al. Cardiovascular Diabetology  (2015) 14:78 Page 10 of 11whose dyslipidemia was thought to be well controlled. To
explore the direct effect of glucose fluctuation on coronary
vulnerability, further study is warranted to include only
patients with more strictly controlled dyslipidemia; i.e.,
LDL <70 mg/dL. Finally, in the present study, we could
not find that the effects of anti-atherosclerotic drugs, such
as statins, α-GI, DPP-4 inhibitors were not independently
associated with the regression of plaque. Although we
could not find the impact of anti-atherosclerotic drugs on
the regression of lipid-rich plaque in this study, further
study is warranted to evaluate whether additional glucose
fluctuation control will decrease the progression of TCFA
and late clinical events.
Conclusions
In this OCT and CGM study focusing on the impact of
glucose fluctuation on plaque properties, daily glucose
fluctuation appeared to have an impact on the formation
of lipid-rich plaque, including TCFA, rather than calcifi-
cation. Moreover, longer time in hypoglycemia may have
some associations on the formation of lipid-rich plaques,
thus supporting the concept that hypoglycemia can beone of the mechanisms of plaque rupture. A large-scale,
randomized study is warranted to validate whether early
detection and control of glucose fluctuation, especially
hypoglycemia, could be beneficial to improve the clinical
outcome of patients with CAD receiving adequate lipid-
lowering therapy.Abbreviations
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